WATCH | EU approves sales of the world's first battery-powered artificial heart
Artificial heartmaker Carmat will begin sales of its devices from the second quarter of 2021 after a long-awaited European Commission approval.
Given recurring shortages of donors, Carmat's device aims to give patients with end-stage biventricular heart failure, a deadly condition where the heart is no longer able to pump blood adequately around the body, an alternative to hospital stays.
Carmat's CEO Stephane Piat said: “The idea behind this heart, which was born nearly 30 years ago, was to create a device which would replace heart transplants, a device that works physiologically like a human heart, one that's pulsating, self-regulated and compatible with blood.”
Piat said the company was striving to secure an extension of the EU approval so that it could cater to people who, because of pre-existing conditions, could not be considered on the waiting list for a heart transplant.
The battery-powered material weighs 900 grams, while a human heart weighs 300 grams, and will cost more than $180,000 (R2.77m).
Would you like to comment on this article or view other readers' comments? Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.